At 3 h post-injection, the CML+apoA-I+CIGB-258 group showed the highest survivability of ~85 ± 3%, while the CML+apoA-I and CML+CIGB-258 groups showed 65 ± 6% and 70 ± 5% survivability, respectively. Here, APOA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.